Audrey Rao
Director/Board Member at Shanghai Ark Biopharmaceutical Co., Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Zheng Wu | M | 60 |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 10 years |
| Sen Quan Zhang | M | 47 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Wen Fang Wu | M | 45 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Min Min Yang | M | 52 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Xu Bo Hu | M | 48 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 4 years |
| Jian Fan | M | 67 |
Nanjing University
| 41 years |
| Hai Qing Yuan | M | 58 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bosheng Zhou | M | 59 |
Nanjing University
| 7 years |
| Ji Shun Liu | M | 67 |
Nanjing University
| 4 years |
| Wei Dong Li | M | 56 |
Nanjing University
| 6 years |
| Long Quan Pan | M | 60 |
Nanjing University
| 6 years |
| Jun Zhou | M | 56 |
Nanjing University
| 4 years |
| Lin Ni | M | 50 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
| Han Song Zhu | M | 54 |
Nanjing University
| 4 years |
| Cheng Bin Qiu | M | 60 |
Nanjing University
| 4 years |
| Yong Qian Wu | M | 61 |
Nanjing University
| 4 years |
| Jian Zhang | M | 59 |
Nanjing University
| 4 years |
| Xiao Kun Wang | F | 53 |
Nanjing University
| 4 years |
| You Gen Li | M | 56 |
Nanjing University
| 4 years |
| Ying Lin Han | M | - |
Nanjing University
| 3 years |
| Wei Zhong | M | 55 |
Nanjing University
| 4 years |
| Dong Qi Qian | M | 66 |
Nanjing University
| 4 years |
| Yun Bin Du | M | 60 |
Nanjing University
| 4 years |
| Li Hua Chen | M | 59 |
Nanjing University
| 4 years |
| Min Peng | F | 60 |
Nanjing University
| 4 years |
| Xiao Guang Duan | M | 68 |
Nanjing University
| 3 years |
| Tom Babka | M | - |
Providence College
| 5 years |
| Andrew Bogart | M | - |
Providence College
| 4 years |
| Wen Yan Zhuang | F | 57 |
Nanjing University
| 4 years |
| Tian Yi Zhang | M | 56 |
Nanjing University
| 4 years |
| Hong Lin Yuan | M | 57 |
Nanjing University
| 4 years |
| Gang Li | M | 61 |
Nanjing University
| 4 years |
| Shu Qian Wang | F | 58 |
Nanjing University
| 3 years |
| Wei Hua Chen | M | 60 |
Nanjing University
| 4 years |
| Su Yue Zhu | F | 61 |
Nanjing University
| 4 years |
| Kelli Finnegan | F | - |
Providence College
| - |
| Yi Che | M | 54 |
Nanjing University
| 4 years |
| Jian Hua Zhao | M | 41 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
| Hu Li | M | 59 |
Nanjing University
| 4 years |
| Hai Sang | M | 67 |
Nanjing University
| 1 years |
| Lei Zhu | M | 59 |
Nanjing University
| 4 years |
| Li Qing Mao | M | 56 |
Nanjing University
| 4 years |
| Zhen Hai Liang | M | 59 |
Nanjing University
| 4 years |
| Jian Ping Zhou | M | 61 |
Nanjing University
| 4 years |
| Wei Ying Zhu | F | 57 |
Nanjing University
| 4 years |
| Pui Chun Suen | F | 45 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
| Hong Gao | M | 56 |
Nanjing University
| 3 years |
| Zhang Shun Xiang | M | 56 |
Nanjing University
| 4 years |
| Hai Xu | M | 58 |
Nanjing University
| 4 years |
| Mike Liu | M | 58 |
Nanjing University
| 4 years |
| Hua Liang Jiang | M | 59 |
Nanjing University
| 4 years |
| Yang Xia | M | 55 |
Nanjing University
| 4 years |
| Chris Lamoriello | M | - |
Providence College
| 4 years |
| Matt Roddy | M | - |
Providence College
| 3 years |
| Zhong Quan Li | M | 60 |
Nanjing University
| 4 years |
| Ji Fan Gao | M | 59 |
Nanjing University
| 4 years |
| Shu Qian Wang | F | 57 |
Nanjing University
| 3 years |
| David G. Richards | M | 51 |
Providence College
| 4 years |
| Shangzhong Xi | M | 61 |
Nanjing University
| 1 years |
| He Liang Fu | M | 63 |
Nanjing University
| 3 years |
| James Jiang | M | - |
Nanjing University
| 4 years |
| Jin Chun Zhang | M | - |
Nanjing University
| 4 years |
| Mei Shuang | F | 56 |
Nanjing University
| 4 years |
| Chen Wei | M | - |
Nanjing University
| 4 years |
| Glen Michael Petraglia | M | - |
Providence College
| 4 years |
| He Dong Shu | M | 60 |
Nanjing University
| 4 years |
| Jia Zhu | M | 61 |
Nanjing University
| 1 years |
| Jian Yu Qian | M | 60 |
Nanjing University
| 4 years |
| Guo Xiao Yong | M | - |
Nanjing University
| 4 years |
| Yi Zhang | F | 57 |
Nanjing University
| 4 years |
| Ling Huan Zhao | M | 61 |
Nanjing University
| 4 years |
| Juan Acevedo | M | - |
Providence College
| 4 years |
| Bing Wen Miao | M | 56 |
Nanjing University
| 4 years |
| Li Lu | M | - |
Nanjing University
| 4 years |
| Andrew Xiao | M | - |
Nanjing University
| 4 years |
| Danke Yu | M | 54 |
Nanjing University
| 4 years |
| Wei Qing Ma | M | 58 |
Nanjing University
| 4 years |
| Patty A. Clarkson | F | - |
Providence College
| 4 years |
| Wei Xiao | F | 54 |
Nanjing University
| 4 years |
| Yao Li | M | 55 |
Nanjing University
| 4 years |
| Guo Jun Qi | M | 61 |
Nanjing University
| 4 years |
| Fang Liang Zhang | M | 59 |
Nanjing University
| 1 years |
| Ren Rong Wang | M | 56 |
Nanjing University
| 4 years |
| Hua Liang Jiang | M | 60 |
Nanjing University
| 4 years |
| Richard Faulkner | M | - |
Providence College
| 4 years |
| Hao Zhang | M | 64 |
Nanjing University
| 4 years |
| Tong Ying Liang | M | 63 |
Nanjing University
| 1 years |
| Ding Xiong Zhang | M | 59 |
Nanjing University
| 4 years |
| Kun Rong Shen | M | 61 |
Nanjing University
| 4 years |
| Hang Shi | M | - |
Nanjing University
| 3 years |
| Xu Yu Zhang | M | 60 |
Nanjing University
| 1 years |
| Zhi Qiang Li | M | 61 |
Nanjing University
| 4 years |
| Ming Song | M | - |
Nanjing University
| 3 years |
| Shao Feng Chen | M | 59 |
Nanjing University
| 1 years |
| Chang Sheng Xu | M | 61 |
Nanjing University
| 4 years |
| Tim Jia | M | - |
Nanjing University
| 4 years |
| Tao Zheng | M | 57 |
Nanjing University
| 4 years |
| Xin Rong Fu | M | 58 |
Nanjing University
| 4 years |
| Wen Long Gu | M | 58 |
Nanjing University
| 4 years |
| De Qun She | M | 59 |
Nanjing University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| China | 90 | 90.00% |
| United States | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Audrey Rao
- Personal Network